JP2021511298A5 - - Google Patents
Info
- Publication number
- JP2021511298A5 JP2021511298A5 JP2020538029A JP2020538029A JP2021511298A5 JP 2021511298 A5 JP2021511298 A5 JP 2021511298A5 JP 2020538029 A JP2020538029 A JP 2020538029A JP 2020538029 A JP2020538029 A JP 2020538029A JP 2021511298 A5 JP2021511298 A5 JP 2021511298A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- siglec
- variable region
- region containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616317P | 2018-01-11 | 2018-01-11 | |
| US62/616,317 | 2018-01-11 | ||
| PCT/US2019/013316 WO2019140273A1 (en) | 2018-01-11 | 2019-01-11 | Anti-siglec-7 antibodies having reduced effector function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511298A JP2021511298A (ja) | 2021-05-06 |
| JP2021511298A5 true JP2021511298A5 (enExample) | 2022-02-07 |
| JP7342005B2 JP7342005B2 (ja) | 2023-09-11 |
Family
ID=67219179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538029A Active JP7342005B2 (ja) | 2018-01-11 | 2019-01-11 | エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11912766B2 (enExample) |
| EP (1) | EP3737410A4 (enExample) |
| JP (1) | JP7342005B2 (enExample) |
| AU (1) | AU2019208025A1 (enExample) |
| CA (1) | CA3087968A1 (enExample) |
| WO (1) | WO2019140273A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180054639A (ko) | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| CN119841953A (zh) * | 2018-06-08 | 2025-04-18 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| WO2023091512A2 (en) * | 2021-11-16 | 2023-05-25 | Allakos, Inc. | Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9 |
| WO2023192992A2 (en) * | 2022-03-31 | 2023-10-05 | The Wistar Institute Of Anatomy And Biology | Bispecific natural killer engagers that target siglec-7 |
| AU2023243622A1 (en) * | 2022-03-31 | 2024-11-14 | The Wistar Institute Of Anatomy And Biology | Antibodies against human siglec-7 and use thereof for immunotherapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070244038A1 (en) | 2006-04-12 | 2007-10-18 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| EP2172483A4 (en) | 2007-07-04 | 2010-08-04 | Forerunner Pharma Res Co Ltd | ANTI-MUC17 ANTIBODY |
| BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| ES2791183T3 (es) | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
| MX383594B (es) * | 2014-08-07 | 2025-03-14 | Daiichi Sankyo Co Ltd | Anticuerpo anti-orai1. |
| WO2016038064A1 (en) * | 2014-09-10 | 2016-03-17 | Innate Pharma | Cross reactive siglec antibodies |
| KR20180054639A (ko) * | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| AU2016356780A1 (en) * | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| AU2017207807A1 (en) | 2016-01-12 | 2018-07-12 | Palleon Pharmaceuticals Inc. | Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer |
| EP3426688A1 (en) | 2016-03-08 | 2019-01-16 | Innate Pharma | Siglec neutralizing antibodies |
| BR112019002331A2 (pt) * | 2016-08-05 | 2019-06-18 | Allakos Inc | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos |
-
2019
- 2019-01-11 US US16/961,197 patent/US11912766B2/en active Active
- 2019-01-11 EP EP19739010.7A patent/EP3737410A4/en not_active Withdrawn
- 2019-01-11 WO PCT/US2019/013316 patent/WO2019140273A1/en not_active Ceased
- 2019-01-11 AU AU2019208025A patent/AU2019208025A1/en not_active Abandoned
- 2019-01-11 CA CA3087968A patent/CA3087968A1/en active Pending
- 2019-01-11 JP JP2020538029A patent/JP7342005B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511298A5 (enExample) | ||
| US12152076B2 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
| JP2024119791A5 (enExample) | ||
| JP2024009818A5 (enExample) | ||
| US12180302B2 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| CN108699136B (zh) | 结合cd3和psma的异二聚抗体 | |
| JP2023528350A5 (enExample) | ||
| JP2021521275A5 (enExample) | ||
| JP2020522266A5 (enExample) | ||
| CN107406512A (zh) | 结合cd3和cd38的异二聚体抗体 | |
| AU2014296215A1 (en) | Stabilization of Fc-containing polypeptides | |
| CA3025310A1 (en) | Compositions and methods related to engineered fc constructs | |
| AU2018358883A1 (en) | Method for in vivo generation of multispecific antibodies from monospecific antibodies | |
| JP2024521131A5 (enExample) | ||
| US20220119549A1 (en) | Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof | |
| JP2022513999A5 (enExample) | ||
| JP2024535712A5 (enExample) | ||
| JP2023541816A5 (enExample) | ||
| CN114174344A (zh) | 工程改造铰链区以驱动抗体二聚化 | |
| JP2023554097A5 (enExample) | ||
| JP2023517660A5 (enExample) | ||
| JP2024524891A5 (enExample) | ||
| JP2025507448A5 (enExample) | ||
| US20240247062A1 (en) | Heterodimeric antibodies that bind claudin18.2 and cd3 | |
| JP2024534034A5 (enExample) |